AccuGenomics and 1Cell.Ai Partner to Enhance Liquid Biopsy Testing Accuracy Across Asia with U.S. Expansion Plans
核心洞察
AccuGenomics (搜索) and 1Cell.Ai (搜索) announced a strategic collaboration to deliver ultra-sensitive liquid biopsy testing through their clinical laboratory in India, serving cancer (搜索) patients across Asia.
The partnership integrates AccuGenomics (搜索)' Accukit™ CRC/NSCLC Internal Standards (搜索) into 1Cell.Ai (搜索)'s OncoIndx panel (搜索) to provide per-sample quality control and reduce false negatives in cancer (搜索) diagnostics.
1Cell.Ai (搜索) expects to process tens of thousands of patient samples in the next year and plans to introduce the enhanced assay at its Foster City, California facility for U.S. market expansion.
AccuGenomics (搜索), Inc., a US-based leader in next-generation sequencing (NGS) quality standards, and 1Cell.Ai (搜索), a precision oncology company specializing in single-cell and liquid biopsy diagnostics, have announced a strategic collaboration to deliver ultra-sensitive, clinically actionable liquid biopsy testing through their clinical laboratory in India serving cancer (搜索) patients across Asia.
Enhanced Quality Control Integration
Under this partnership, 1Cell.Ai (搜索) will integrate AccuGenomics (搜索)' Accukit™ CRC/NSCLC Internal Standards (搜索) into its ultra-sensitive NGS-based OncoIndx panel (搜索) to provide per-sample quality control and sensitivity verification. The company expects to process tens of thousands of patient samples in the next year, significantly increasing access to high-precision cancer (搜索) testing across Asia.
The Accukit™ CRC/NSCLC Internal Standards (搜索) are synthetic, gene-specific quality controls that validate assay performance and ensure sensitivity for detecting clinically relevant mutations in colorectal cancer (搜索) (CRC) and non-small cell lung cancer (搜索) (NSCLC). By embedding internal standards within every patient sample tested, laboratories can confirm per-sample analytical accuracy, improve reproducibility, and reduce false negatives, a critical advancement in clinical NGS testing where small-variant detection directly influences patient management and therapeutic decisions.
Market Expansion Strategy
1Cell.Ai (搜索) also plans to introduce this assay at its Foster City, California facility to support precision multi-omic testing for the United States market soon. The company operates a CLIA and CAP certified laboratory at Foster City, California, offering innovative Laboratory Developed tests (LDTs) and first-in-class assays for next-generation cell-based liquid biopsies with true single-cell multi-omic biomarker analytics.
Industry Leadership Perspectives
"We are thrilled to partner with 1Cell.Ai (搜索), a leader in multi-omic precision diagnostics," said Nick Lazaridis, President of AccuGenomics (搜索). "By integrating our Accukit™ CRC/NSCLC Internal Standards (搜索) with their liquid biopsy platform, we are enabling true per-sample sensitivity and reliability, a new benchmark in cancer (搜索) diagnostics. This collaboration not only strengthens cancer care in India but also lays the groundwork for their expansion into the US market."
"This collaboration represents a significant step forward in ensuring that every patient sample we analyze meets the highest standards of analytical accuracy," said Mohan Uttarwar, CEO of 1Cell.Ai (搜索). "By integrating AccuGenomics (搜索)' internal standards into our OncoIndx gene-panel, we can deliver ultra-sensitive, clinically actionable insights for oncologists and patients. This partnership supports our mission to make precision oncology testing both reliable and affordable, first across Asia, and soon in the United States."
Company Profiles
AccuGenomics (搜索), Inc. is a biotechnology tools company headquartered in Wilmington, North Carolina, specializing in the development of synthetic internal standards for next-generation sequencing (NGS). The company's Accukit™ product line provides per-sample quality control and LOD sensitivity assurance, enabling clinical laboratories and diagnostic developers to improve test diagnostic accuracy, reproducibility, and confidence in genomic data.
1Cell.Ai (搜索) is a US-based precision oncology company with presence in Mumbai and Pune, India. The company aims to transform cancer (搜索) diagnostics and advance the future of precision medicine by delivering comprehensive, real-time insights that empower clinicians, researchers, and biopharma partners to make informed, personalized decisions. Financial terms of the agreement were not disclosed.